Insider trading

Period: 120 months Stock: ANGO Plan: Not on a plan × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

37 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

37 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

37 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

37 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
37 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
37 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

37 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
30 Jul 2026
Nighan Warren JR SVP Quality and Regulatory
Sold at will
$344.01K 23,370 at 14.72
26.5%
Not planned
21 Oct 2025
Weiss Lawrence T SVP, Chief Legal Officer
Bought
$118.10K 10,000 at 11.81
12.0%
First buy on file
13 Oct 2025
Trowbridge Stephen A EVP and CFO
Bought
$9.93K 890 at 11.16
0.3%
9 Oct 2025
Clemmer James C President and CEO
Bought
$111.50K 10,000 at 11.15
1.1%
16 Jan 2025
Nighan Warren JR SVP Quality and Regulatory
Sold at will
$49.98K 4,060 at 12.31
8.8%
Not planned
10 Oct 2024
Nighan Warren JR SVP Quality and Regulatory
Bought
$608.00 100 at 6.08
0.2%
8 Oct 2024
Trowbridge Stephen A EVP and CFO
Bought
$9.96K 1,700 at 5.86
1.0%
7 Oct 2024
Nighan Warren JR SVP Quality and Regulatory
Bought
$4.68K 768 at 6.09
1.7%
First buy on file
8 Apr 2024
Clemmer James C President and CEO
Bought
$67.00K 10,000 at 6.70
1.9%
31 Jan 2023
Helsel Dave SVP Global Operations and R&D
Sold, plan not stated
$60.00K 4,633 at 12.95
19.4%
12 Oct 2022
Trowbridge Stephen A EVP and CFO
Bought
$14.97K 1,083 at 13.82
1.2%
10 Oct 2022
Clemmer James C President and CEO
Bought
$150.00K 10,000 at 15.00
2.3%
29 Jul 2022
Helsel Dave SVP Global Operations and R&D
Sold, plan not stated
$112.20K 5,000 at 22.44
17.3%
28 Apr 2022
Helsel Dave SVP Global Operations and R&D
Sold, plan not stated
$78.83K 3,513 at 22.44
13.3%
12 Apr 2022
JOHNSON WESLEY Director
Sold, plan not stated
$30.21K 1,299 at 23.26
1.6%
11 Apr 2022
JOHNSON WESLEY Director
Sold, plan not stated
$142.62K 6,201 at 23.00
7.2%
12 Jan 2022
Trowbridge Stephen A EVP and CFO
Bought
$22.64K 1,000 at 22.64
1.3%
First buy on file
11 Jan 2022
Clemmer James C President and CEO
Bought
$228.40K 10,000 at 22.84
2.6%
First buy on file
20 Oct 2021
Helsel Dave SVP Global Operations and R&D
Sold, plan not stated
$97.73K 3,494 at 27.97
11.7%
15 Oct 2021
Centea Scott Sr. VP/GM, Global VIT
Sold, plan not stated
$335.04K 12,000 at 27.92
20.6%
5 Oct 2021
Campbell Chad Thomas SVP/GM, Vascular Access
Sold, plan not stated
$291.81K 10,748 at 27.15
25.3%
14 Apr 2021
Helsel Dave SVP Global Operations and R&D
Sold, plan not stated
$83.76K 3,500 at 23.93
15.5%
20 Jan 2021
JOHNSON WESLEY Director
Sold, plan not stated
$120.45K 6,500 at 18.53
7.7%
11 Aug 2020
Trowbridge Stephen A EVP and CFO
Bought
$9.50K 1,013 at 9.38
1.7%
First buy on file
31 Jul 2020
Clemmer James C President and CEO
Bought
$330.40K 40,000 at 8.26
13.2%
First buy on file
25 Oct 2019
Clemmer James C President and CEO
Bought
$212.85K 15,000 at 14.19
6.1%
First buy on file
16 Jul 2019
Gould Kevin J Director
Sold, plan not stated
$292.79K 13,650 at 21.45
19.8%
7 Nov 2018
Greiner Michael EVP and CFO
Sold, plan not stated
$41.75K 1,939 at 21.53
8.6%
15 Nov 2017
Richard Stark SVP, GM - Oncology
Sold, plan not stated
$446.49K 27,409 at 16.29
56.9%
Sold half or more
24 Jul 2017
REED JAN STERN Director
Bought
$5.06K 316 at 16.00
opened
First buy on file
21 Jul 2017
Clemmer James C President and CEO
Bought
$78.95K 5,000 at 15.79
5.8%
First buy on file
21 Jul 2017
Bought
$78.60K 5,000 at 15.72
11.7%
First buy on file
20 Jul 2017
Clemmer James C President and CEO
Bought
$312.80K 20,000 at 15.64
30.0%
First buy on file
12 Apr 2017
Avista Capital Partners GP, LLC 10% owner · indirect
Sold, plan not stated 3×
$37.60M 2,350,000 at 16.00
86.0%
Sold half or more
12 Apr 2017
Burgstahler David F Director · indirect
Sold, plan not stated 3×
$37.60M 2,350,000 at 16.00
86.0%
Sold half or more
18 Nov 2016
Burgstahler David F Director · indirect
Sold, plan not stated 2×
$32.79M 2,091,294 at 15.68
67.3%
Sold half or more
18 Nov 2016
Avista Capital Partners GP, LLC 10% owner · indirect
Sold, plan not stated 2×
$32.79M 2,091,294 at 15.68
67.3%
Sold half or more
Showing 1–37 of 37.